Welcome to our dedicated page for Blackstone news (Ticker: BX), a resource for investors and traders seeking the latest updates and insights on Blackstone stock.
Blackstone Inc (BX), the world's largest alternative asset manager, provides investors with transformative opportunities across private equity, real estate, and credit markets. This dedicated news hub delivers essential updates directly from corporate sources and trusted financial publications.
Access real-time announcements including quarterly earnings reports, strategic acquisitions, and leadership developments. Our curated feed simplifies tracking Blackstone's global investment activities across infrastructure, life sciences, and sustainability initiatives.
Key updates cover:
- Financial performance and dividend declarations
- Portfolio company milestones and exits
- Regulatory filings and compliance updates
- Industry analysis impacting alternative assets
Bookmark this page for streamlined monitoring of Blackstone's market position and strategic direction. Combine our timely updates with fundamental analysis tools for comprehensive investment research.
Blackstone (NYSE:BX) announced the launch of Uniquity Bio, a clinical-stage drug development company specializing in immunology and inflammation. Blackstone has committed $300 million in financing to advance Uniquity Bio's lead asset, solrikitug, a monoclonal antibody targeting TSLP. The FDA has accepted Uniquity Bio's Phase 2 IND application for solrikitug, which will be tested in chronic obstructive pulmonary disease (COPD) and asthma. These conditions affect millions globally, with COPD being the third leading cause of death worldwide. Solrikitug, in-licensed from Merck, aims to provide best-in-class efficacy for unmet needs in respiratory and GI indications. Uniquity Bio's leadership team combines global pharma standards with biotech agility, supported by Blackstone’s capital and expertise.
Blackstone Secured Lending Fund (NYSE: BXSL) announced a public offering of $400 million in 5.875% unsecured notes due 2027. The notes will mature on November 15, 2027, and can be redeemed in part or whole at BXSL's discretion.
The net proceeds are intended for general corporate purposes, including investments and debt repayment. The offering is expected to close on May 20, 2024, subject to customary conditions. Joint book-running managers include Citigroup, Barclays, Goldman Sachs, RBC Capital Markets, and SMBC Nikko Securities America.
Investors are advised to review the prospectus and related documents for details on investment objectives, risks, charges, and expenses. The offer is based on a shelf registration statement filed with the SEC.
Blackstone (BX) appoints Philip Sherrill as Global Head of Insurance, focusing on growing the firm's insurance platform globally, leveraging scale to serve clients and drive performance. The platform has tripled in size since 2020, exceeding $200 billion in assets under management. Sherrill brings extensive experience from Global Atlantic Financial Group and Goldman Sachs.
Blackstone Real Estate Partners X and Blackstone Real Estate Income Trust, Inc. have completed the privatization of Tricon Residential Inc. for a total equity transaction value of $3.5 billion. Tricon remains committed to developing new single-family homes and apartments in the U.S. and Canada, with plans to invest $1 billion in capital projects. The partnership aims to enhance the quality of existing homes and provide affordable housing. The transaction involves a cash offer of $11.25 per Common Share. Blackstone will maintain an 11.6% ownership stake post-closing. The Common Shares are expected to be de-listed from NYSE and TSX on May 2, 2024, with Tricon ceasing to be a reporting issuer. Detailed information on the Transaction is available in the Circular and on SEDAR+ and SEC websites.
FAQ
What is the current stock price of Blackstone (BX)?
What is the market cap of Blackstone (BX)?
